Logo
Europe Pharmacogenomics Market 2020-2030

Europe Pharmacogenomics Market 2020-2030

Bonafide Trust 28-09-2020 125 Pages Figures : 50 Tables : 38
Region : Europe Category : Lifescience Biotechnology

Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services